Litcius/Paper detail

Second line treatment of acromegaly: Pasireotide or Pegvisomant?

Sabrina Chiloiro, Antonio Bianchi, Antonella Giampietro, Alfredo Pontecorvi, Gérald Raverot, Laura De Marinis

2022Best Practice & Research Clinical Endocrinology & Metabolism19 citationsDOI

Topics & Concepts

AcromegalyPasireotidePegvisomantMedicineDiseaseSomatostatinInternal medicineOctreotideOncologyEndocrinologyGrowth hormoneHormonePituitary Gland Disorders and TreatmentsGrowth Hormone and Insulin-like Growth FactorsNeuroendocrine Tumor Research Advances
Second line treatment of acromegaly: Pasireotide or Pegvisomant? | Litcius